CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease
Hepatobiliary Surg Nutr
.
2023 Aug 1;12(4):593-594.
doi: 10.21037/hbsn-23-247.
Epub 2023 Jul 6.
Authors
Yinhan Wang
1
,
Haifeng Xu
1
Affiliation
1
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences (CAMS), Beijing, China.
PMID:
37600998
PMCID:
PMC10432308
DOI:
10.21037/hbsn-23-247
No abstract available
Keywords:
CRISPR; drug screening; non-alcoholic fatty liver disease (NAFLD); organoids.
Publication types
Editorial